British MedTech company Occuity has published key clinical trial results in the Journal of Ophthalmic & Physiological Optics. The trial was conducted to analyze the repeatability of central corneal thickness (CCT) measurements taken with the company’s PM1 pachymeter.

CCT is an important clinical measurement in the diagnosis and management of glaucoma and corneal dystrophies. The Occuity PM1 is a handheld, non-contact pachymeter that uses confocal technology to measure CCT.

The trials found that the device showed excellent precision for CCT measurements across a range of corneal thicknesses in normal eyes. The trial also found that the PM1 pachymeter provided a safe and easy-to-use alternative to ultrasound pachymetry that could facilitate an increased uptake of pachymetry in routine optometric practice.

The report concluded that “the PM1 pachymeter shows excellent precision for CCT measurements across a range of corneal thicknesses in normal eyes and provides a safe and easy-to-use alternative to ultrasound pachymetry.”

The clinical trial was conducted by a team of experienced optometrists including Professor John Lawrenson of City University and Simranjit Gill, Isra Masuid and Fardip Rashid of Moorfields Eye Hospital.

“With the clinical trials demonstrating that the performance of the PM1 is excellent and comparable to current market options, we’re confident that with its significant non-contact, handheld advantages, the PM1 offers an excellent solution,” said Dan Daly, CEO of Occuity. “We’re looking forward to introducing the PM1 to the market and have signed up distributors across Europe and are now in conversations with distributors in APAC and North America.”

Occuity is currently in the process of CE marking the PM1 ahead of its release later this year.